Seeing a return on investment in pharma marketing means understanding what happens to every dollar.
Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.
Our new advice for the Blues, who are in a formative period as market trends create both sizable risk and sizable opportunity.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.
Some of our 2017 healthcare predictions on value-based care, consumers, mergers, startups, and pharma came true, while others were less predictable.
As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.
Trendspotting in unpredictable times. This infographic highlights five predictions for 2017.
Through this series of infographics, learn how payers, providers, and life sciences companies will be impacted by our 45th president.
The Deal features David Campbell on how healthcare companies can leverage royalties, not their balance sheets, to fund innovation.